Short-Course versus Standard-Course Antibiotic Therapy for Pneumonia in Adult: A Systematic Review
DOI:
https://doi.org/10.58344/ihj.v5i2.876Keywords:
pneumonia, anti-bacterial agents, drug administration schedule, treatment outcome, adultAbstract
Pneumonia remains a significant cause of morbidity and mortality among adults worldwide, with substantial impacts on healthcare utilization and costs. Despite advancements in vaccines, diagnostics, and antimicrobial therapy, optimizing antibiotic duration remains a clinical challenge. Traditional regimens typically span 7–14 days, but prolonged therapy contributes to antimicrobial resistance, adverse events, and higher healthcare expenses. This study aims to evaluate the effectiveness and safety of short-course (?7 days) versus standard-course (?7 days) antibiotic therapy in adult patients with pneumonia. A systematic review was conducted following PRISMA guidelines, including randomized controlled trials and observational studies published between 2016 and 2026. Data on clinical cure, mortality, recurrence, hospital length of stay, and adverse events were extracted and analyzed. Results from seven studies involving 5,467 patients indicate that short-course therapy is generally non-inferior to standard-course therapy in terms of clinical cure and mortality, particularly among patients achieving early clinical stability. Recurrence rates were comparable, while some studies demonstrated reduced hospital stay and fewer antibiotic-related adverse events in short-course groups. These findings support individualized treatment durations guided by clinical response rather than fixed periods. In conclusion, short-course antibiotic therapy is an effective and safe strategy for appropriately selected adult patients with pneumonia, offering potential benefits for patient outcomes, antimicrobial stewardship, and healthcare resource optimization.
References
Bienvenu, A. L., Ducrocq, J. M., Augé-Caumon, M. J., & Baseilhac, E. (2025). Clinical decision support system to guide antimicrobial selection: A narrative review from 2019 to 2023. Journal of Hospital Infection, 162, 140–152.
Bouglé, A., Tuffet, S., Federici, L., Leone, M., Monsel, A., Dessalle, T., Amour, J., Fizelier, C. D., Barbier, F., Luyt, C. E., Langeron, O., Cholley, B., Pottecher, J., Hissem, T., Lefrant, J. Y., Veber, B., & Legrand, M. (2022). Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: A randomized, controlled, open-label trial. Intensive Care Medicine, 841–849. https://doi.org/10.1007/s00134-022-06690-5
Daghmouri, M. A., Dudoignon, E., Chaouch, M. A., et al. (2023). Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine, 58, 101880. https://doi.org/10.1016/j.eclinm.2023.101880
Dimopoulou, D., Moschopoulos, C. D., Dimopoulou, K., et al. (2024). Duration of antimicrobial treatment in adult patients with pneumonia: A narrative review. Antibiotics, 13(11). https://doi.org/10.3390/antibiotics13111078
Dinh, A., Ropers, J., Duran, C., Davido, B., Deconinck, L., Matt, M., Senard, O., Lagrange, A., & Makhloufi, S. (n.d.). Discontinuing ?-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): A double-blind, randomized, placebo-controlled, non-inferiority trial. The Lancet, 1195–1203. https://doi.org/10.1016/S0140-6736(21)00313-5
Furukawa, Y., Luo, Y., Funada, S., et al. (2023). Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: A systematic review and duration-effect meta-analysis. BMJ Open, 13(3), e061023. https://doi.org/10.1136/bmjopen-2022-061023
Furlan, L., Erba, L., Trombetta, L., et al. (2019). Short- vs long-course antibiotic therapy for pneumonia: A comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign. Internal and Emergency Medicine, 14(3), 377–394. https://doi.org/10.1007/s11739-018-1955-2
Gonçalves-Pereira, J., Froes, F., Pereira, F. G., Diniz, A., Oliveira, H., & Mergulhão, P. (2025). Community-acquired pneumonia mortality trends according to age and gender: 2009 to 2019. BMC Pulmonary Medicine, 25(1), 391. https://doi.org/10.1186/s12890-025-03875-8
Israelsen, S. B., Fally, M., Tarp, B., Kolte, L., Ravn, P., & Ben, T. (2023). Short-course antibiotic therapy for hospitalized patients with early clinical response in community-acquired pneumonia: A multicentre cohort study. Clinical Microbiology and Infection, 29, 54–60. https://doi.org/10.1016/j.cmi.2022.08.004
Kato, H. (2024). Antibiotic therapy for bacterial pneumonia. Journal of Pharmaceutical Health Care and Sciences, 10(1), 45. https://doi.org/10.1186/s40780-024-00367-5
Khowaja, R., & Karimi, F. (2023). Comparison of short-course versus long-course antibiotic treatment for community-acquired pneumonia: A meta-analysis of randomized controlled trials. 10(10), 3832–3838.
Llor, C. (2025). Shifting the mindset regarding adherence to antibiotic use for respiratory tract infections. Exploratory Research in Clinical and Social Pharmacy, 18, 100588. https://doi.org/10.1016/j.rcsop.2025.100588
Llor, C., Frimodt-Møller, N., Miravitlles, M., Kahlmeter, G., & Bjerrum, L. (2024). Optimising antibiotic exposure by customising the duration of treatment for respiratory tract infections based on patient needs in primary care. EClinicalMedicine, 74, 102723. https://doi.org/10.1016/j.eclinm.2024.102723
Mo, Y., Booraphun, S., Li, A. Y., Domthong, P., Kayastha, G., Lau, Y. H., Chetchotisakd, P., Limmathurotsakul, D., Tambyah, P. A., & Cooper, B. S. (2024). Individualised short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): A multicentre study. The Lancet Respiratory Medicine, 2600(23), 1–11. https://doi.org/10.1016/S2213-2600(23)00418-6
Peiffer-Smadja, N. (2021). Evaluation and implementation of clinical decision support tools for antimicrobial stewardship (Doctoral dissertation). Université Paris Cité.
Pennisi, F., Pinto, A., Ricciardi, G. E., Signorelli, C., & Gianfredi, V. (2025). The role of artificial intelligence and machine learning models in antimicrobial stewardship in public health: A narrative review. Antibiotics, 14(2), 134.
Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E., Herrero, P., Hayhoe, B., Hope, W., Georgiou, P., & Holmes, A. H. (2017). A systematic review of clinical decision support systems for antimicrobial management: Are we failing to investigate these interventions appropriately? Clinical Microbiology and Infection, 23(8), 524–532.
Salam, M. A., Al-Amin, M. Y., Salam, M. T., et al. (2023). Antimicrobial resistance: A growing serious threat for global public health. Healthcare, 11(13). https://doi.org/10.3390/healthcare11131946
Uranga, A., España, P. P., Bilbao, A., Quintana, J. M., Arriaga, I., Intxausti, M., Lobo, J. L., Tomás, L., Camino, J., Nuñez, J., & Capelastegui, A. (2016). Duration of antibiotic treatment in community-acquired pneumonia: A multicenter randomized clinical trial. JAMA Internal Medicine, 176(9), 1257–1265. https://doi.org/10.1001/jamainternmed.2016.3633
Wang, B., Gui, S., Mei, J., & Zou, Z. (2026). Short- versus long-course antibiotic therapy in mechanically ventilated sepsis patients with pneumonia: A real-world cohort analysis. 81.
Yayan, J., & Rasche, K. (2026). Timing of antibiotics in ICU pneumonia: An observational association between early treatment and higher mortality. Antibiotics, 15(1). https://doi.org/10.3390/antibiotics15010049
Zhao, T., Chen, L., Wang, P., Tian, G., Ye, F., Zhu, H., & He, B. (2016). A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia. Journal of Thoracic Disease, 87(9), 2473–2484. https://doi.org/10.21037/jtd.2016.08.30
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ni Wayan Devi Yulian, I Made Satria Wibawa
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
